Assembly Biosciences (ASMB) Cash from Investing Activities (2011 - 2026)

Assembly Biosciences' Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$5.4 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 181.72% year-over-year to -$5.4 million in Q1 2026; TTM through Mar 2026 was -$125.4 million, a 525.42% decrease from a year earlier, with the FY2025 full-year figure at -$113.5 million, down 382.46% from the prior year.
• Cash from Investing Activities retreated to -$5.4 million in Q1 2026 per ASMB's latest filing, from $21.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $33.0 million in Q1 2022 and bottomed at -$158.3 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is $10.0 million (2023), against an average of -$3.4 million.
• Biggest YoY gain for Cash from Investing Activities was 416.95% in 2025; the steepest drop was 746.32% in 2025.
• Year by year, Cash from Investing Activities stood at $16.6 million in 2022, then tumbled by 641.32% to -$89.7 million in 2023, then soared by 92.53% to -$6.7 million in 2024, then jumped by 416.95% to $21.2 million in 2025, then sank by 125.36% to -$5.4 million in 2026.
• Per Business Quant, the three latest ASMB Cash from Investing Activities figures stand at -$5.4 million (Q1 2026), $21.2 million (Q4 2025), and -$158.3 million (Q3 2025).